Pharmaceuticals, Biotechnology and Life Sciences
Results from the second interim analysis of the Phase 3 SPARTAN study featured in an oral presentation at ESMO 2019…
Company appoints Flexion Therapeutics CEO Mike Clayman as board chairman DURHAM, N.C.–(BUSINESS WIRE)–Ribometrix, a biotechnology company developing small molecule therapeutics…
TORONTO & BOSTON–(BUSINESS WIRE)–Northern Biologics Inc., a company focused on developing first-in-class oncology products, today announced the presentation of updated…
NEW YORK–(BUSINESS WIRE)–Following its regularly scheduled meeting, the Board of Directors of Pfizer Inc. (NYSE:PFE) today announced that Executive Chairman…
— First patient in the global Phase 3 program enrolled — — Approximately one in 100 adults and one in…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Phase 2 MoveDMD trial and open-label…
LOUGHBOROUGH, England–(BUSINESS WIRE)–Nemaura Pharma Limited, a UK based Biopharmaceutical company specializing in transdermal and injectable drug delivery systems today announced…
Ipsen got approval for Dysport, the first and only FDA-approved botulinum toxin for treatment of both pediatric upper and lower limb spasticity, as the pivotal Phase 3 study showed Dysport improved spasticity symptoms in children aged two to 17 experiencing upper limb spasticity, as measured by the primary efficacy endpoint of Modified Ashworth Scale at elbow or wrist flexors at Week 6.
Nevome Biotherapeutics has started testing its ST266 when delivered intranasally in a Phase 1 open label clinical trial, in patients diagnosed with intraocular hypertension who have not yet developed optic nerve damage, with topline results expected by end of the second quarter of 2020.
BERKELEY, Calif.–(BUSINESS WIRE)–On September 19, 2019, a three-member JAMS panel issued an Interim Award in the arbitration between Intellia Therapeutics,…